{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:38:41Z","timestamp":1794242321290,"version":"4.9.0"},"reference-count":150,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Chronic myeloid leukemia is one of the onco-hematologic diseases in which the identification of disease markers and therapeutic advances have been particularly impactful. Despite this, significant gaps remain in our understanding of disease pathogenesis, progression, mechanisms of immune escape, and resistance to standard therapies. Recently, advances in technology and biological knowledge have drawn attention to several promising areas of research. Among these, leukemic stem cells, miRNAs, extracellular vesicles, and additional BCR::ABL1 mutations, with particular reference to the <jats:italic>ASXL1<\/jats:italic> gene, have been the most extensively investigated. In this review we summarized and critically commented the main findings on these key topics over the past 5 years, evaluating their potential impact on patient management and their role in the development of new therapeutic strategies.<\/jats:p>","DOI":"10.3389\/fonc.2025.1546813","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T04:11:02Z","timestamp":1746677462000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers"],"prefix":"10.3389","volume":"15","author":[{"given":"Anna","family":"Sicuranza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Cavalleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101196","DOI":"10.1016\/j.blre.2024.101196","article-title":"Chronic myeloid leukaemia: Biology and therapy","volume":"65","author":"Wang","year":"2024","journal-title":"Blood Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.3390\/ijms25063307","article-title":"Clinical insights into structure, regulation, and targeting of ABL kinases in human leukemia","volume":"25","author":"Wu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27359","article-title":"BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis","volume":"99","author":"Kockerols","year":"2024","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1159\/000510440","article-title":"RT-qPCR versus digital PCR: how do they impact differently on clinical management of chronic myeloid leukemia patients","volume":"13","author":"Zanaglio","year":"2020","journal-title":"Case Rep Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v10.5","article-title":"Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study","volume":"10","author":"Malagola","year":"2021","journal-title":"Cancer Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.3390\/jcm9123865","article-title":"Molecular testing in CML between old and new methods: are we at a turning point","volume":"9","author":"Soverini","year":"2020","journal-title":"J Clin Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.01.008","article-title":"The italian multicentric randomized OPTkIMA trial on fixed vs progressive intermittent TKI therapy in CML elderly patients: 3-years of molecular response and quality of life monitoring after completing the treatment plan","volume":"24","author":"Malagola","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e496","DOI":"10.1097\/HS9.0000000000000496","article-title":"Digital PCR for BCR-ABL1 quantification in CML: current applications in clinical practice","volume":"4","author":"Kockerols","year":"2020","journal-title":"Hemasphere"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-06100-4","article-title":"Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study","volume":"104","author":"Bernardi","year":"2024","journal-title":"Ann Hematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.3390\/jcm9061709","article-title":"Chronic myeloid leukemia prognosis and therapy: criticisms and perspectives","volume":"9","author":"Russo","year":"2020","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"20406207231216077","DOI":"10.1177\/20406207231216077","article-title":"Twenty years of evolution of CML therapy: how the treatment goal is moving from disease to patient","volume":"14","author":"Russo","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024657","article-title":"Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study","volume":"144","author":"Yeung","year":"2024","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1186\/s12885-024-12764-y","article-title":"Application of artificial intelligence in chronic myeloid leukemia (CML) disease prediction and management: a scoping review","volume":"24","author":"Ram","year":"2024","journal-title":"BMC Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/ajh.26047","article-title":"The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes","volume":"96","author":"Sasaki","year":"2020","journal-title":"Am J Hematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3390\/cancers16050848","article-title":"Artificial intelligence-based management of adult chronic myeloid leukemia: where are we and where are we going","volume":"16","author":"Bernardi","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1186\/s12885-022-10094-5","article-title":"Three-dimensional nuclear telomere architecture and differential expression of aurora kinase genes in chronic myeloid leukemia to measure cell transformation","volume":"22","author":"de Oliveira","year":"2022","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.3390\/cancers15092594","article-title":"Modeling global genomic instability in chronic myeloid leukemia (CML) using patient-derived induced pluripotent stem cells (iPSCs)","volume":"15","author":"Telliam","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2147\/JBM.S382090","article-title":"Chronic myeloid leukemia, from pathophysiology to treatment-free remission: A narrative literature review","volume":"14","author":"Rinaldi","year":"2023","journal-title":"J Blood Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"11795549221139356","DOI":"10.1177\/11795549221139357","article-title":"Current management of chronic myeloid leukemia myeloid blast phase","volume":"16","author":"Yohanan","year":"2022","journal-title":"Clin Med Insights Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1389450121999201013152513","article-title":"Computational and biological investigations on abl1 tyrosine kinase: A review","volume":"22","author":"Sobhia","year":"2021","journal-title":"Curr Drug Targets"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.3390\/cancers15164112","article-title":"Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR)","volume":"15","author":"Abruzzese","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40164-020-00183-1","article-title":"Expression differences of miR-142-5p between treatment-na\u00efve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance","volume":"9","author":"Kl\u00fcmper","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2015_115","article-title":"microRNA expression profiling as supportive diagnostic and therapy prediction tool in chronic myeloid leukemia","volume":"62","author":"Jurkovicova","year":"2015","journal-title":"Neoplasma"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.193086","article-title":"BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia","volume":"103","author":"Srutova","year":"2018","journal-title":"Haematologica"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1159\/000505088","article-title":"Exosomes in chronic myeloid leukemia: are we reading a new reliable message","volume":"143","author":"Bernardi","year":"2020","journal-title":"Acta Haematol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.3390\/cancers14184504","article-title":"Feasibility of leukemia-derived exosome enrichment and co-isolated dsDNA sequencing in acute myeloid leukemia patients: A proof of concept for new leukemia biomarkers detection","volume":"14","author":"Bernardi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000448","article-title":"Atypical CML: diagnosis and treatment","volume":"2023","author":"Breccia","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41408-022-00742-1","article-title":"Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia","volume":"12","author":"Bidikian","year":"2022","journal-title":"Blood Cancer J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1038\/s41375-022-01648-4","article-title":"ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia","volume":"36","author":"Sch\u00f6nfeld","year":"2022","journal-title":"Leukemia"},{"key":"B32","doi-asserted-by":"publisher","first-page":"147776","DOI":"10.1016\/j.gene.2023.147776","article-title":"Frequency and prognostic influence of ASXL1 mutations and its potential association with BCR-ABL1 transcript type and smoke in chronic myeloid leukemia patients","volume":"886","author":"Rafiq Mohammed","year":"2023","journal-title":"Gene"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.v100.3","article-title":"Mutation of epigenetic regulators at diagnosis is an independent predictor of tyrosine kinase inhibitor treatment failure in chronic myeloid leukemia: A report from the RESIDIAG study","volume":"100","author":"Guerineau","year":"2025","journal-title":"Am J Hematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.v194.3","article-title":"Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up","volume":"194","author":"Romzova","year":"2021","journal-title":"Br J Haematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1159\/000506452","article-title":"A case of tyrosine kinase inhibitor-resistant chronic myeloid leukemia, chronic phase with ASXL1 mutation","volume":"13","author":"Imataki","year":"2020","journal-title":"Case Rep Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26318","article-title":"Leukemia stem cells","volume":"129","author":"Buss","year":"2011","journal-title":"Int J Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2010","journal-title":"J Clin Invest"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00555","article-title":"The polycomb BMI1 protein is co-expressed with CD26+ in leukemic stem cells of chronic myeloid leukemia","volume":"8","author":"Galimberti","year":"2018","journal-title":"Front Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3390\/cancers14040891","article-title":"CD26\/DPP-4 in chronic myeloid leukemia","volume":"14","author":"Sicuranza","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12368","article-title":"DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia","volume":"44","author":"Valent","year":"2014","journal-title":"Eur J Clin Invest"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-536078","article-title":"(CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia","volume":"123","author":"Herrmann","year":"2014","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/cyto.b.21764","article-title":"Flow cytometry assessment of CD26+ Leukemic stem cells in peripheral blood: A simple and rapid new diagnostic tool for chronic myeloid leukemia","volume":"96","author":"Raspadori","year":"2019","journal-title":"Cytomet B Clin Cytom"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00194","article-title":"Residual peripheral blood CD26+ Leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission","volume":"8","author":"Bocchia","year":"2018","journal-title":"Front Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204689","article-title":"FATE and role of peripheral blood CD26+ Leukemia STEM CELLS at diagnosis in chronic myeloid leukemia patients: FINAL results of prospective flowers study","volume":"144","author":"Sicuranza","year":"2024","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1194712","article-title":"Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26+ leukemia stem cells","volume":"14","author":"Pacelli","year":"2023","journal-title":"Front Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"RP92074","DOI":"10.7554\/eLife.92074.3.sa3","article-title":"Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response","volume":"12","author":"Warfvinge","year":"2024","journal-title":"Elife"},{"key":"B47","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3324\/haematol.2024.285071","article-title":"Single-cell proteo-transcriptomic profiling reveals altered characteristics of stem and progenitor cells in patients receiving cytoreductive hydroxyurea in early-phase chronic myeloid leukemia","volume":"110","author":"Komic","year":"2024","journal-title":"Haematologica"},{"key":"B48","doi-asserted-by":"publisher","first-page":"16671","DOI":"10.3390\/ijms242316671","article-title":"Stem cell responsiveness to imatinib in chronic myeloid leukemia","volume":"24","author":"Lahlil","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","first-page":"217060","DOI":"10.1016\/j.canlet.2024.217060","article-title":"HIF-2\u03b1 inhibition disrupts leukemia stem cell metabolism and impairs vascular microenvironment to enhance chronic myeloid leukemia treatment","volume":"597","author":"Wang","year":"2024","journal-title":"Cancer Lett"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-022-00762-w","article-title":"YBX1 regulates the survival of chronic myeloid leukemia stem cells by modulating m6A-mediated YWHAZ stability","volume":"46","author":"Chai","year":"2023","journal-title":"Cell Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41467-024-44771-9","article-title":"Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease","volume":"15","author":"Scott","year":"2024","journal-title":"Nat Commun"},{"key":"B52","first-page":"6042","article-title":"PI3-kinase inhibition as a strategy to suppress the leukemic stem cell niche in Ph+ chronic myeloid leukemia","volume":"11","author":"Filik","year":"2021","journal-title":"Am J Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1691\/ph.2021.1744","article-title":"CD44: a potential therapeutic target in chronic myeloid leukemia","volume":"76","author":"Rui","year":"2021","journal-title":"Pharmazie"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.612573","article-title":"miRNome profiling of LSC-enriched CD34+CD38\u2013CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool","volume":"11","author":"Ruiz","year":"2021","journal-title":"Front Pharmacol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2014.00337","article-title":"A non-canonical landscape of the microRNA system","volume":"5","author":"Cipolla","year":"2014","journal-title":"Front Genet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1750-3639.2007.00121.x","article-title":"MicroRNAs: biogenesis and molecular functions","volume":"18","author":"Liu","year":"2008","journal-title":"Brain Pathol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1111\/j.1349-7006.2010.01650.x","article-title":"Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis","volume":"101","author":"Kosaka","year":"2010","journal-title":"Cancer Sci"},{"key":"B59","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1042\/BC20070078","article-title":"microRNAs: small molecules with big roles \u2013C. elegans to human cancer","volume":"100","author":"Kato","year":"2008","journal-title":"Biol Cell"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.708765","article-title":"Tumor suppressor miRNA in cancer cells and the tumor microenvironment: mechanism of deregulation and clinical implications","volume":"11","author":"Otmani","year":"2021","journal-title":"Front Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.848199","article-title":"A systematic review of candidate miRNAs, its targeted genes and pathways in chronic myeloid leukemia\u2013an integrated bioinformatical analysis","volume":"12","author":"Elias","year":"2022","journal-title":"Front Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/genes15081054","article-title":"Gene variants in components of the microRNA processing pathway in chronic myeloid leukemia","volume":"15","author":"Chavaro-Francisco","year":"2024","journal-title":"Genes (Basel)"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.3390\/ijms25063363","article-title":"The screening of microRNAs in chronic myeloid leukemia: A clinical evaluation","volume":"25","author":"Wosniaki","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.2217\/bmm-2023-0575","article-title":"Dysregulation of miRNA expression in patients with chronic myelogenous leukemia at diagnosis: A systematic review","volume":"17","author":"Parsa-Kondelaji","year":"2023","journal-title":"Biomark Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12032-023-02278-1","article-title":"Role of miRNAs to control the progression of Chronic Myeloid Leukemia by their expression levels","volume":"41","author":"Bansal","year":"2024","journal-title":"Med Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"120437","DOI":"10.1016\/j.lfs.2022.120437","article-title":"The role of microRNAs in the development, progression and drug resistance of chronic myeloid leukemia and their potential clinical significance","volume":"296","author":"Navabi","year":"2022","journal-title":"Life Sci"},{"key":"B67","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3390\/ijms26010415","article-title":"Dual Roles of miR-10a-5p and miR-10b-5p as Tumor Suppressors and Oncogenes in Diverse Cancers","volume":"26","author":"Singh","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B68","article-title":"MiR-15a-5p negatively regulates cell survival and metastasis by targeting CXCL10 in chronic myeloid leukemia","volume":"9","author":"Chen","year":"2017","journal-title":"Am J Transl Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11033-025-10359-9","article-title":"mir-188-5p emerges as an oncomir to promote chronic myeloid leukemia via upregulation of BUB3 and SUMO2","volume":"52","author":"Akidan","year":"2025","journal-title":"Mol Biol Rep"},{"key":"B70","doi-asserted-by":"publisher","first-page":"12516","DOI":"10.1016\/j.omtn.2023.04.026","article-title":"Genetic biomarkers in chronic myeloid leukemia: what have we learned so far","volume":"22","author":"Abdulmawjood","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2023.04.026","article-title":"PPFIA1- targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration","volume":"32","author":"Su","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1159\/000524158","article-title":"MiR-199a-3p overexpression suppressed cell proliferation and sensitized chronic myeloid leukaemia cells to imatinib by inhibiting mTOR signalling","volume":"145","author":"Liu","year":"2022","journal-title":"Acta Haematol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41419-021-04209-2","article-title":"Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance","volume":"12","author":"Wu","year":"2021","journal-title":"Cell Death Dis"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2019.20.8.2379","article-title":"microRNA-21 expression as prognostic and therapeutic response marker in chronic myeloid leukaemia patients","volume":"20","author":"Mirza","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2020-001563","article-title":"Circulating miR-146a expression predicts early treatment response to imatinib in adult chronic myeloid leukemia","volume":"69","author":"Habib","year":"2021","journal-title":"J Invest Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1159\/000518722","article-title":"Regulation of miR-126 and miR-122 Expression and Response of Imatinib Treatment on Its Expression in Chronic Myeloid Leukemia Patients","volume":"44","author":"Ali Beg","year":"2021","journal-title":"Oncol Res Treat"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2304488","DOI":"10.1080\/16078454.2024.2304488","article-title":"Correlation analysis of bone marrow microvessel density and miRNA expression on drug resistance in patients with chronic myelogenous leukemia after tyrosine kinase inhibitor treatment","volume":"29","author":"Guo","year":"2024","journal-title":"Hematology"},{"key":"B78","article-title":"The synergistic effect of miR-203 and cytarabine on the inhibition of cell proliferation and induction of apoptosis in chronic myelogenous leukemia cells","volume":"37","author":"Qi","year":"2024","journal-title":"Pak J Pharm Sci"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2024.2433687","article-title":"miR-181a: regulatory roles, cancer-associated signaling pathway disruptions, and therapeutic potential","volume":"28","author":"McIntyre","year":"2024","journal-title":"Expert Opin Ther Targets"},{"key":"B80","doi-asserted-by":"publisher","first-page":"7156","DOI":"10.3390\/ijms22137156","article-title":"Dysregulation of miRNA in Leukemia: Exploiting miRNA Expression Profiles as Biomarkers","volume":"22","author":"Anelli","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1173970","article-title":"Profiling of miRNAs and their interfering targets in peripheral blood mononuclear cells from patients with chronic myeloid leukaemia","volume":"13","author":"Wu","year":"2023","journal-title":"Front Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biology9090258","article-title":"Extracellular vesicles: from biomarkers to therapeutic tools","volume":"9","author":"Bernardi","year":"2020","journal-title":"Biol (Basel)"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00277-020-04109-z","article-title":"dsDNA from extracellular vesicles (EVs) in adult AML","volume":"100","author":"Bernardi","year":"2020","journal-title":"Ann Hematol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1239042","article-title":"Extracellular vesicles in the Chronic Myeloid Leukemia scenario: an update about the shuttling of disease markers and therapeutic molecules","volume":"13","author":"Bernardi","year":"2023","journal-title":"Front Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/biology10020105","article-title":"Exosomes and extracellular vesicles in myeloid neoplasia: the multiple and complex roles played by these \u201cMagic bullets","volume":"10","author":"Bernardi","year":"2021","journal-title":"Biol (Basel)"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2020.5163","article-title":"Exosomes released by imatinib-resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib-sensitive cells in the presence of imatinib","volume":"58","author":"Hrdinova","year":"2021","journal-title":"Int J Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2017.116","article-title":"BCR-ABL1-positive microvesicles Malignantly transform human bone marrow mesenchymal stem cells in vitro","volume":"38","author":"Fu","year":"2017","journal-title":"Acta Pharmacol Sin"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.2217\/bmm-2019-0510","article-title":"Basic knowledge on bcr-abl1-positive extracellular vesicles","volume":"14","author":"Jurj","year":"2020","journal-title":"Biomark Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.3892\/ijmm.2019.4372","article-title":"Feasibility of tumor-derived exosome enrichment in the onco-hematology leukemic model of chronic myeloid leukemia","volume":"44","author":"Bernardi","year":"2019","journal-title":"Int J Mol Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-185733","article-title":"Correlation between BCR::ABL1 transcript LEVEL in circulating extracellular vesicles and BOTH the molecular response and the ongoing therapy: A study on adult CML patients","volume":"142","author":"Bernardi","year":"2023","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1239042","article-title":"Extracellular vesicles in the Chronic Myeloid Leukemia scenario: an update about the shuttling of disease markers and therapeutic molecules","volume":"13","author":"Bernardi","year":"2024","journal-title":"Front Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00432-024-05915-y","article-title":"Effects of exosomes and inflammatory response on tumor: a bibliometrics study and visualization analysis via CiteSpace and VOSviewer","volume":"150","author":"Yu","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3390\/cancers13061203","article-title":"Immunosuppressive cell subsets and factors in myeloid leukemias","volume":"13","author":"Swatler","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2741\/4901","article-title":"Crosstalk between CML cells with HUVECs and BMSCs through exosomes","volume":"26","author":"Cetin","year":"2021","journal-title":"Front Biosci - Landmark"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3934\/mbe.2023864","article-title":"Bayesian analysis of the effect of exosomes in a mouse xenograft model of chronic myeloid leukemia","volume":"20","author":"Mart\u00ednez-Fonseca","year":"2023","journal-title":"Math Biosci Eng"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11033-024-09383-y","article-title":"Platelet microparticles influence gene expression and modulate biological activities of chronic myeloid leukemia cells (K562)","volume":"51","author":"Nikravesh","year":"2024","journal-title":"Mol Biol Rep"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3111","article-title":"Using natural killer cell-derived exosomes as a cell-free therapy for leukemia","volume":"41","author":"Samara","year":"2023","journal-title":"Hematol Oncol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/cancers16010090","article-title":"NK3.3-derived extracellular vesicles penetrate and selectively kill treatment-resistant tumor cells","volume":"16","author":"McCune","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2019.10.096","article-title":"K562 cell-derived exosomes suppress the adhesive function of bone marrow mesenchymal stem cells via delivery of miR-711","volume":"521","author":"Jiang","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"B100","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41419-022-04531-3","article-title":"HucMSC exosomes promoted imatinib-induced apoptosis in K562-R cells via a miR-145a-5p\/USP6\/GLS1 axis","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"key":"B101","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1080\/16078454.2024.2379597","article-title":"Extracellular vesicle-mediated regulation of imatinib resistance in chronic myeloid leukemia via the miR-629-5p\/SENP2\/PI3K\/AKT\/mTOR axis","volume":"29","author":"Jiang","year":"2024","journal-title":"Hematology"},{"key":"B102","doi-asserted-by":"publisher","first-page":"8607","DOI":"10.3390\/ijms24108607","article-title":"The miRNA content of bone marrow-derived extracellular vesicles contributes to protein pathway alterations involved in ionising radiation-induced bystander responses","volume":"24","author":"Csord\u00e1s","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B103","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.7150\/thno.83178","article-title":"BCR-ABL1-driven exosome-miR130b-3p-mediated gap-junction Cx43 MSC intercellular communications imply therapies of leukemic subclonal evolution","volume":"13","author":"Chai","year":"2023","journal-title":"Theranostics"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1182\/bloodadvances.2021006195","article-title":"4-1BBL\u2013containing leukemic extracellular vesicles promote immunosuppressive effector regulatory T cells","volume":"6","author":"Swatler","year":"2022","journal-title":"Blood Adv"},{"key":"B105","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/eji.201848051","article-title":"Chronic myeloid leukemia-derived extracellular vesicles increase Foxp3 level and suppressive activity of thymic regulatory T cells","volume":"50","author":"Swatler","year":"2019","journal-title":"Eur J Immunol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1186\/s12885-021-08734-3","article-title":"CML derived exosomes promote tumor favorable functional performance in T cells","volume":"21","author":"Jafarzadeh","year":"2021","journal-title":"BMC Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00373","article-title":"The dawn of allosteric BCR-ABL1 drugs: from a phenotypic screening hit to an approved drug","volume":"65","author":"Teng","year":"2022","journal-title":"J Med Chem"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1446517","article-title":"Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy","volume":"14","author":"George","year":"2024","journal-title":"Front Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.03.009","article-title":"The clinical significance of BCR-ABL1 mutations in patients with philadelphia chromosome\u2013positive chronic myeloid leukemia who underwent allogeneic hematopoietic cell transplantation","volume":"28","author":"Tachibana","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B110","doi-asserted-by":"publisher","first-page":"13057","DOI":"10.1038\/s41598-022-17271-3","article-title":"Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA","volume":"12","author":"S\u00e1nchez","year":"2022","journal-title":"Sci Rep"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3892\/ol.2020.11650","article-title":"Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosis","volume":"20","author":"Liu","year":"2020","journal-title":"Oncol Lett"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01662-3","article-title":"Asciminib: first approval","volume":"82","author":"Deeks","year":"2022","journal-title":"Drugs"},{"key":"B113","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.3324\/haematol.2022.282361","article-title":"Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery","volume":"108","author":"Padala","year":"2023","journal-title":"Haematologica"},{"key":"B114","doi-asserted-by":"publisher","first-page":"103580","DOI":"10.1016\/j.critrevonc.2022.103580","article-title":"Development of asciminib, a novel allosteric inhibitor of BCR-ABL1","volume":"171","author":"R\u00e9a","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2464494","article-title":"Asciminib in the treatment of chronic myeloid leukemia in chronic phase","volume":"21","author":"Costa","year":"2025","journal-title":"Future Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0157-2","article-title":"Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia","volume":"32","author":"Ernst","year":"2018","journal-title":"Leukemia"},{"key":"B117","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1038\/bcj.2013.54","article-title":"ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia","volume":"3","author":"Menezes","year":"2013","journal-title":"Blood Cancer J"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03510-w","article-title":"Genetic landscape of chronic myeloid leukemia","volume":"117","author":"Ochi","year":"2023","journal-title":"Int J Hematol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1217153","article-title":"Case Report: ASXL1, RUNX1, and IDH1 mutation in tyrosine kinase-independent resistant chronic myeloid leukemia progressing to chronic myelomonocytic leukemia-like accelerated phase","volume":"13","author":"Oyogoa","year":"2023","journal-title":"Front Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.64.369","article-title":"Clinical significance of clonal evolution in chronic myeloid leukemia","volume":"64","author":"Ochi","year":"2023","journal-title":"Rinsho Ketsueki"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cas.70007","article-title":"CML with mutant ASXL1 showed decreased sensitivity to TKI treatment via upregulation of the ALOX5-BLTR signaling pathway","author":"Miyashita","year":"2025","journal-title":"Cancer Sci"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S257661","article-title":"Integrative genomic analysis reveals cancer-associated gene mutations in chronic myeloid leukemia patients with resistance or intolerance to tyrosine kinase inhibitor","volume":"13","author":"Wu","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B123","doi-asserted-by":"publisher","first-page":"101194","DOI":"10.1016\/j.beha.2020.101194","article-title":"CML - Not only BCR-ABL1 matters","volume":"33","author":"Rinke","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.04.014","article-title":"Genetic heterogeneity in chronic myeloid leukemia: how clonal hematopoiesis and clonal evolution may influence prognosis, treatment outcome, and risk of cardiovascular events","volume":"21","author":"Sant\u2019Antonio","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-024-01808-9","article-title":"Significance of somatic mutation profiling in CML beyond BCR-ABL: A retrospective study of the Indian population","volume":"41","author":"Chaudhary","year":"2025","journal-title":"Indian J Hematol Blood Transfus"},{"key":"B126","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/bs.ircmb.2021.02.010","article-title":"Lab tests for MPN","volume":"366","author":"Moncada","year":"2022","journal-title":"Int Rev Cell Mol Biol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12943-024-02109-5","article-title":"A high proportion of germline variants in pediatric chronic myeloid leukemia","volume":"23","author":"Krumbholz","year":"2024","journal-title":"Mol Cancer"},{"key":"B128","doi-asserted-by":"publisher","first-page":"12816","DOI":"10.1038\/s41598-022-17232-w","article-title":"Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model","volume":"12","author":"Kazemi-Sefat","year":"2022","journal-title":"Sci Rep"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep16030045","article-title":"Clinical validation of the somatic FANCD2 mutation (c.2022-5C>T) as a novel molecular biomarker for early disease progression in chronic myeloid leukemia: A case\u2013control study","volume":"16","author":"Alanazi","year":"2024","journal-title":"Hematol Rep"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-209165","article-title":"Impact of non-ABL1 mutations on outcomes in patients with chronic myeloid leukemia","volume":"144","author":"Jain","year":"2024","journal-title":"Blood"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283059","article-title":"New patterns of genetic instability in chronic myeloid leukemia: interesting, but not ready for clinical use","volume":"108","author":"Schiffer","year":"2023","journal-title":"Haematologica"},{"key":"B132","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/blood-2023-187636","article-title":"Impact of mutations in blood cancer-related genes on clinical outcomes in chronic myeloid leukemia in chronic phase (CML-CP) after \u22652 tyrosine kinase inhibitors (TKIs) in the ascembl trial","volume":"142","author":"Branford","year":"2023","journal-title":"Blood"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205465","article-title":"ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial","volume":"144","author":"Soverini","year":"2024","journal-title":"Blood"},{"key":"B134","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3390\/cancers14030620","article-title":"Genomic mechanisms influencing outcome in chronic myeloid leukemia","volume":"14","author":"Fernandes","year":"2022","journal-title":"Cancers"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1938534","article-title":"Measuring prognosis in chronic myeloid leukemia: what\u2019s new","volume":"14","author":"Breccia","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.7335","article-title":"Beyond BCR::ABL1\u2014The role of genomic analyses in the management of CML","volume":"22","author":"Branford","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"key":"B137","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/BS9.0000000000000129","article-title":"BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia","volume":"4","author":"Zhang","year":"2022","journal-title":"Blood Sci"},{"key":"B138","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03331-x","article-title":"Secondary chronic myeloid leukemia in a patient with CALR and ASXL1-mutated primary myelofibrosis","volume":"116","author":"Sobieralski","year":"2022","journal-title":"Int J Hematol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.3390\/cancers14235752","article-title":"Targeted next-generation sequencing identifies additional mutations other than BCR\u2237ABL in chronic myeloid leukemia patients: A chinese monocentric retrospective study","volume":"14","author":"Hu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B141","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.3390\/ijms22052595","article-title":"Sex-related differences in chronic myeloid neoplasms: from the clinical observation to the underlying biology","volume":"22","author":"Karantanos","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B142","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.3324\/haematol.2022.282184","article-title":"Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention","volume":"108","author":"Shanmuganathan","year":"2023","journal-title":"Haematologica"},{"key":"B143","doi-asserted-by":"publisher","first-page":"10214","DOI":"10.3390\/ijms251810214","article-title":"Genomic landscape of myelodysplastic\/myeloproliferative neoplasms: A multi-central study","volume":"25","author":"Fei","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1354750X.2024.2304187","article-title":"The role of ASXL1 mutations and ASXL1 CircRNAs in cancer","volume":"29","author":"Jafarbeik-Iravani","year":"2024","journal-title":"Biomarkers"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27553","article-title":"Mutation of epigenetic regulators at diagnosis is an independent predictor of tyrosine kinase inhibitor treatment failure in chronic myeloid leukemia: A report from the RESIDIAG study","volume":"100","author":"Guerineau","year":"2024","journal-title":"Am J Hematol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3390\/cells9071639","article-title":"EZH2 in myeloid Malignancies","volume":"9","author":"Rinke","year":"2020","journal-title":"Cells"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/BLCTT.S228815","article-title":"Strategies for targeting chronic myeloid leukaemia stem cells","volume":"9","author":"Carr\u00e0","year":"2019","journal-title":"Blood Lymphat Cancer"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.70007","article-title":"Different in vitro models of chronic myeloid leukemia show different characteristics: biological replicates are not biologically equivalent","volume":"49","author":"Cavalleri","year":"2025","journal-title":"Cell Biol Int"},{"key":"B150","doi-asserted-by":"publisher","first-page":"101521","DOI":"10.1016\/j.xcrm.2024.101521","article-title":"Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia","volume":"5","author":"Adnan Awad","year":"2024","journal-title":"Cell Rep Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1546813\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T04:11:04Z","timestamp":1746677464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1546813\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":150,"alternative-id":["10.3389\/fonc.2025.1546813"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1546813","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"article-number":"1546813"}}